Organization
Mayo Clinic Department of Oncology
4 abstracts
Abstract
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).Org: Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, Duke University Medical Center/Duke Cancer Institute,
Abstract
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.Org: Ontario Institute for Cancer Research, Toronto, ON, Canada, MASS General Hospital BHX-1, Mayo Clinic Department of Oncology, Progendis, Caris Life Sciences,
Abstract
The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer.Org: Mayo Clinic, Mayo Clinic Department of Oncology,
Abstract
Characteristics associated with spatially resolved immune landscapes in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.Org: Ultima Genomics, NanoString Technologies, Inc., Helsinki University Hospital and University of Helsinki, Mayo Clinic Alliance Statistics and Data Center, Mayo Clinic Department of Oncology,